Amgen reported flat third-quarter revenues and a 14% decline in net income, accompanied by tempered guidance for the full year. While there is optimism around the Prolia launch and pipeline developments, the immediate financial indicators and cautious outlook are likely to weigh on investor sentiment in the short term.

[-1]